Universal access to malaria medicines: innovation in financing and delivery.

PubWeight™: 3.31‹?› | Rank: Top 1%

🔗 View Article (PMID 20940074)

Published in Lancet on November 27, 2010

Authors

Olusoji Adeyi1, Rifat Atun

Author Affiliations

1: Global Fund to Fight AIDS, Tuberculosis and Malaria, Geneva, Switzerland. Olusoji.Adeyi@Theglobalfund.org

Articles citing this

Got ACTs? Availability, price, market share and provider knowledge of anti-malarial medicines in public and private sector outlets in six malaria-endemic countries. Malar J (2011) 2.99

The ACTwatch project: methods to describe anti-malarial markets in seven countries. Malar J (2011) 2.03

Socially-marketed rapid diagnostic tests and ACT in the private sector: ten years of experience in Cambodia. Malar J (2011) 1.93

Recent clinical and molecular insights into emerging artemisinin resistance in Plasmodium falciparum. Curr Opin Infect Dis (2011) 1.68

Private sector drug shops in integrated community case management of malaria, pneumonia, and diarrhea in children in Uganda. Am J Trop Med Hyg (2012) 1.67

Methods for implementing a medicine outlet survey: lessons from the anti-malarial market. Malar J (2013) 1.37

Do patients adhere to over-the-counter artemisinin combination therapy for malaria? evidence from an intervention study in Uganda. Malar J (2012) 1.28

Access to artesunate-amodiaquine, quinine and other anti-malarials: policy and markets in Burundi. Malar J (2011) 1.20

Closing the access barrier for effective anti-malarials in the private sector in rural Uganda: consortium for ACT private sector subsidy (CAPSS) pilot study. Malar J (2012) 0.98

Do price subsidies on artemisinin combination therapy for malaria increase household use? Evidence from a repeated cross-sectional study in remote regions of Tanzania. PLoS One (2013) 0.98

Communicating the AMFm message: exploring the effect of communication and training interventions on private for-profit provider awareness and knowledge related to a multi-country anti-malarial subsidy intervention. Malar J (2014) 0.96

Understanding the impact of subsidizing artemisinin-based combination therapies (ACTs) in the retail sector--results from focus group discussions in rural Kenya. PLoS One (2013) 0.95

Has Tanzania embraced the green leaf? Results from outlet and household surveys before and after implementation of the Affordable Medicines Facility-malaria. PLoS One (2014) 0.91

The challenge to avoid anti-malarial medicine stock-outs in an era of funding partners: the case of Tanzania. Malar J (2014) 0.90

Access to artemisinin-combination therapy (ACT) and other anti-malarials: national policy and markets in Sierra Leone. PLoS One (2012) 0.84

Measuring the AMFm. Lancet (2011) 0.83

The Affordable Medicines Facility-malaria (AMFm): are remote areas benefiting from the intervention? Malar J (2015) 0.83

Do frontline health care providers know enough about artemisinin-based combination therapy to rationally treat malaria? A cross-sectional survey in Gezira State, Sudan. Malar J (2015) 0.82

Artemisinin combination therapies price disparity between government and private health sectors and its implication on antimalarial drug consumption pattern in Morogoro Urban District, Tanzania. BMC Res Notes (2012) 0.78

Media, health workers, and policy makers' relationship and their impact on antimalarial policy adoption: a population genetics perspective. Malar Res Treat (2011) 0.77

Gibberellin biosynthetic inhibitors make human malaria parasite Plasmodium falciparum cells swell and rupture to death. PLoS One (2012) 0.76

Budget Impact Analysis of Using Dihydroartemisinin-Piperaquine to Treat Uncomplicated Malaria in Children in Tanzania. Pharmacoeconomics (2016) 0.75

Measuring the AMFm. Lancet (2011) 0.75

Articles by these authors

(truncated to the top 100)

Towards an improved investment approach for an effective response to HIV/AIDS. Lancet (2011) 11.89

An assessment of interactions between global health initiatives and country health systems. Lancet (2009) 10.53

Expansion of cancer care and control in countries of low and middle income: a call to action. Lancet (2010) 6.84

UK investments in global infectious disease research 1997-2010: a case study. Lancet Infect Dis (2012) 5.42

Technologies for global health. Lancet (2012) 5.05

Prevention of mother-to-child transmission of HIV and the health-related Millennium Development Goals: time for a public health approach. Lancet (2011) 5.00

Equity and adequacy of international donor assistance for global malaria control: an analysis of populations at risk and external funding commitments. Lancet (2010) 3.73

Mobile phone messaging for facilitating self-management of long-term illnesses. Cochrane Database Syst Rev (2012) 3.70

Mobile phone messaging reminders for attendance at healthcare appointments. Cochrane Database Syst Rev (2012) 2.87

Is operational research delivering the goods? The journey to success in low-income countries. Lancet Infect Dis (2012) 2.62

Risk factors for pulmonary tuberculosis in Russia: case-control study. BMJ (2005) 2.44

Mobile phone messaging reminders for attendance at healthcare appointments. Cochrane Database Syst Rev (2013) 2.42

Mobile phone messaging for preventive health care. Cochrane Database Syst Rev (2012) 2.15

Economic returns to investment in AIDS treatment in low and middle income countries. PLoS One (2011) 1.98

Tuberculosis diagnostics and biomarkers: needs, challenges, recent advances, and opportunities. J Infect Dis (2012) 1.89

Funding for malaria control 2006-2010: a comprehensive global assessment. Malar J (2012) 1.87

Guidance for evidence-informed policies about health systems: rationale for and challenges of guidance development. PLoS Med (2012) 1.81

Social, economic, human rights and political challenges to global mental health. Ment Health Fam Med (2011) 1.72

Drug-resistant tuberculosis--current dilemmas, unanswered questions, challenges, and priority needs. J Infect Dis (2012) 1.72

Market failure and the poverty of new drugs in maternal health. PLoS Med (2008) 1.70

Scale-up of services and research priorities for diagnosis, management, and control of tuberculosis: a call to action. Lancet (2010) 1.69

Guidance for evidence-informed policies about health systems: linking guidance development to policy development. PLoS Med (2012) 1.68

Integrating tuberculosis and HIV services in low- and middle-income countries: a systematic review. Trop Med Int Health (2012) 1.66

Lives saved by tuberculosis control and prospects for achieving the 2015 global target for reducing tuberculosis mortality. Bull World Health Organ (2011) 1.64

Global health initiative investments and health systems strengthening: a content analysis of global fund investments. Global Health (2013) 1.60

International and national policy challenges in mental health. Ment Health Fam Med (2011) 1.58

An analysis of GAVI, the Global Fund and World Bank support for human resources for health in developing countries. Health Policy Plan (2012) 1.58

Relative and absolute addressability of global disease burden in maternal and perinatal health by investment in R&D. Trop Med Int Health (2011) 1.57

Health systems strengthening: a common classification and framework for investment analysis. Health Policy Plan (2010) 1.56

Health system challenges and solutions to improving mental health outcomes. Ment Health Fam Med (2011) 1.53

Beyond borders: public-health surveillance. Lancet (2006) 1.49

Public-private partnerships for hospitals. Bull World Health Organ (2006) 1.46

Integrating prevention of mother-to-child HIV transmission (PMTCT) programmes with other health services for preventing HIV infection and improving HIV outcomes in developing countries. Cochrane Database Syst Rev (2011) 1.41

Health systems, systems thinking and innovation. Health Policy Plan (2012) 1.41

Integrating prevention of mother-to-child HIV transmission programs to improve uptake: a systematic review. PLoS One (2012) 1.40

Tuberculosis in prisons in sub-Saharan Africa--the need for improved health services, surveillance and control. Tuberculosis (Edinb) (2011) 1.40

Rethinking health systems strengthening: key systems thinking tools and strategies for transformational change. Health Policy Plan (2012) 1.34

Systematic analysis of funding awarded for antimicrobial resistance research to institutions in the UK, 1997-2010. J Antimicrob Chemother (2013) 1.34

Effect of investment in malaria control on child mortality in sub-Saharan Africa in 2002-2008. PLoS One (2011) 1.32

Prevention of HIV/AIDS among injecting drug users in Russia: opportunities and barriers to scaling-up of harm reduction programmes. Health Policy (2007) 1.31

Health systems, communicable diseases and integration. Health Policy Plan (2010) 1.29

Mental health and the global agenda: core conceptual issues. Ment Health Fam Med (2011) 1.28

Why do health systems matter? Exploring links between health systems and HIV response: a case study from Russia. Health Policy Plan (2010) 1.23

Mobile phone messaging for communicating results of medical investigations. Cochrane Database Syst Rev (2012) 1.23

Scaling up research and learning for health systems: time to act. Lancet (2008) 1.22

Positive spill-over effects of ART scale up on wider health systems development: evidence from Ethiopia and Malawi. J Int AIDS Soc (2011) 1.22

Antimicrobial prescribing patterns for respiratory diseases including tuberculosis in Russia: a possible role in drug resistance? J Antimicrob Chemother (2004) 1.19

Differences in research funding for women scientists: a systematic comparison of UK investments in global infectious disease research during 1997-2010. BMJ Open (2013) 1.17

Long-term costs and health impact of continued global fund support for antiretroviral therapy. PLoS One (2011) 1.16

The uptake of integrated perinatal prevention of mother-to-child HIV transmission programs in low- and middle-income countries: a systematic review. PLoS One (2013) 1.14

Global Fund financing of public-private mix approaches for delivery of tuberculosis care. Trop Med Int Health (2011) 1.11

Systematic analysis of funding awarded for norovirus research to institutions in the United Kingdom, 1997-2010. J R Soc Med (2013) 1.10

Mental health reform in the Russian Federation: an integrated approach to achieve social inclusion and recovery. Bull World Health Organ (2007) 1.08

Investments in respiratory infectious disease research 1997-2010: a systematic analysis of UK funding. BMJ Open (2014) 1.05

Long-term care of AIDS and non-communicable diseases. Lancet (2011) 1.04

Viewpoint: Scientific dogmas, paradoxes and mysteries of latent Mycobacterium tuberculosis infection. Trop Med Int Health (2011) 1.03

Implementing the global plan to stop TB, 2011-2015--optimizing allocations and the Global Fund's contribution: a scenario projections study. PLoS One (2012) 1.01

Scaling up towards international targets for AIDS, tuberculosis, and malaria: contribution of global fund-supported programs in 2011-2015. PLoS One (2011) 1.01

Eliminating tuberculosis and tuberculosis-HIV co-disease in the 21st century: key perspectives, controversies, unresolved issues, and needs. J Infect Dis (2012) 0.99

Tuberculosis and tuberculosis/HIV/AIDS-associated mortality in Africa: the urgent need to expand and invest in routine and research autopsies. J Infect Dis (2012) 0.99

Infectious disease research investments follow colonial ties: questionable ethics. Int Health (2014) 0.97

HIV epidemics and prevention responses in Asia and Eastern Europe: lessons to be learned? AIDS (2010) 0.96

Research on implementation of interventions in tuberculosis control in low- and middle-income countries: a systematic review. PLoS Med (2012) 0.95

Interactions between critical health system functions and HIV/AIDS, tuberculosis and malaria programmes. Health Policy Plan (2010) 0.95

Adoption of rapid diagnostic tests for the diagnosis of malaria, a preliminary analysis of the Global Fund program data, 2005 to 2010. PLoS One (2012) 0.94

Global health priorities and research funding--authors' reply. Lancet Infect Dis (2013) 0.93

A conceptual and analytical approach to comparative analysis of country case studies: HIV and TB control programmes and health systems integration. Health Policy Plan (2010) 0.93

The Global Fund's resource allocation decisions for HIV programmes: addressing those in need. J Int AIDS Soc (2011) 0.90

Investing in improved performance of national tuberculosis programs reduces the tuberculosis burden: analysis of 22 high-burden countries, 2002-2009. J Infect Dis (2012) 0.90

Changing HIV treatment eligibility under health system constraints in sub-Saharan Africa: investment needs, population health gains, and cost-effectiveness. AIDS (2016) 0.90

Public-private partnership in cord blood banking. BMJ (2008) 0.88

Should development agencies care about mental health? Ment Health Fam Med (2011) 0.88

Innovating for impact: the Affordable Medicines Facility-malaria (AMFm). Nat Med (2009) 0.87

Negative health system effects of Global Fund's investments in AIDS, tuberculosis and malaria from 2002 to 2009: systematic review. JRSM Short Rep (2012) 0.87

Expanding the generation and use of economic and financial data to improve HIV program planning and efficiency: a global perspective. J Acquir Immune Defic Syndr (2011) 0.87

Indicators measuring the performance of malaria programs supported by the global fund in Asia, progress and the way forward. PLoS One (2011) 0.87

Know your epidemic, know your response: targeting HIV in Asia. AIDS (2010) 0.87

Emergence of multilateral proto-institutions in global health and new approaches to governance: analysis using path dependency and institutional theory. Global Health (2013) 0.86

Unemployment, government healthcare spending, and cerebrovascular mortality, worldwide 1981-2009: an ecological study. Int J Stroke (2015) 0.86

Sexual and reproductive health activities in HIV programmes: can we monitor progress? J Epidemiol Community Health (2010) 0.86

Venice Statement on global health initiatives and health systems. Lancet (2009) 0.85

SMS text message healthcare appointment reminders in England. J Ambul Care Manage (2008) 0.85

Sex, drugs and economic behaviour in Russia: a study of socio-economic characteristics of high risk populations. Int J Drug Policy (2010) 0.84

Systematic analysis of funding awarded for mycology research to institutions in the UK, 1997-2010. BMJ Open (2014) 0.83

HPTN 052 and the future of HIV treatment and prevention. Lancet (2011) 0.83

Global Fund investments in harm reduction from 2002 to 2009. Int J Drug Policy (2012) 0.83

How can mental health be integrated into health system strengthening? Ment Health Fam Med (2011) 0.81

The effects of Global Fund financing on health governance in Brazil. Global Health (2012) 0.81

Mental health care reforms in Europe: Rehabilitation and social inclusion of people with mental illness in Russia. Psychiatr Serv (2010) 0.80

Scaling up mental health services: where would the money come from? Ment Health Fam Med (2011) 0.80

Global fund financing of tuberculosis services delivery in prisons. J Infect Dis (2012) 0.80

What action can national and international agencies take? Ment Health Fam Med (2011) 0.79

Infectious disease research investments: systematic analysis of immunology and vaccine research funding in the UK. Vaccine (2013) 0.78

Seizing the opportunity to close the cancer divide. Lancet (2013) 0.78

Bridging the divide. J Acquir Immune Defic Syndr (2011) 0.77

HIV in Asia: universal access in sight. AIDS (2010) 0.77

Maternal mortality for 181 countries, 1980-2008. Lancet (2010) 0.77

Public-private partnerships in health: time for evidence-based policies. Heart (2008) 0.75

Telephone consultation for improving health of people living with or at risk of HIV: a systematic review. PLoS One (2012) 0.75

Asia can afford universal access for AIDS prevention and treatment. AIDS (2010) 0.75